Clinical Trials
12 trialsNCT06305754 2026-05-22
MK-2870-009
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT00532155 2025-09-10
VITAL
Sanofi
Phase 3 Completed
NCT04786964 2025-04-02
CONTERNO
Checkpoint Therapeutics, Inc.
Phase 3 Terminated
NCT02578680 2024-09-20
MK-3475-189
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03950674 2024-06-10
MK-3475-189
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03033511 2021-07-29
MERU
AbbVie
Phase 3 Terminated
NCT03061812 2021-02-23
TAHOE
AbbVie
Phase 3 Completed
NCT04201769 2020-04-03
LUNG-NEPA
Consorzio Oncotech
Phase 3 Unknown
NCT03334487 2018-12-26
Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer
AbbVie
Phase 3 Withdrawn
NCT00806819 2017-02-02
Lume Lung 2 : BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC
Boehringer Ingelheim
Phase 3 Completed
NCT00891761 2015-04-17
A Study of IV Casopitant for the Prevention of Nausea and Vomiting Caused By Cisplatin-Based Highly Emetogenic Chemotherapy
GlaxoSmithKline
Phase 3 Withdrawn
NCT00403065 2013-08-26
Dexamethasone and Supportive Care With or Without Whole-Brain Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer That Has Spread to the Brain and Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 3 Completed